Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
γδ T cells plus tislelizumab for advanced lung adenocarcinoma (dose finding and preliminary efficacy)
ChiCTR2600125506Phase 2Not yet recruiting
- Sponsor
- Oncology Department, Northern Theater Command General Hospital
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab and Vγ9Vδ2 T cells in Non-small cell lung cancer adenocarcinoma (NSCLC) (5 arms), sponsored by Oncology Department, Northern Theater Command General Hospital. Primary endpoint: Objective Response Rate. Planned start May 2026; status: not yet recruiting.
02
Drugs
tislelizumabVγ9Vδ2 T cells
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600125506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125506.